WO2014194030A3 - Conjugates comprising cell-binding agents and cytotoxic agents - Google Patents
Conjugates comprising cell-binding agents and cytotoxic agents Download PDFInfo
- Publication number
- WO2014194030A3 WO2014194030A3 PCT/US2014/039919 US2014039919W WO2014194030A3 WO 2014194030 A3 WO2014194030 A3 WO 2014194030A3 US 2014039919 W US2014039919 W US 2014039919W WO 2014194030 A3 WO2014194030 A3 WO 2014194030A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- conjugates
- cell
- cytotoxic
- agents
- cba
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
The invention provides a branched linker compound with reactive moieties for forming covalent bonds with multiple cytotoxic agents (drugs) and/or a cell-binding agent (CBA); a cytotoxic compound comprising a branched linker moiety with a reactive group for forming a CBA-drug conjugates; a modified cell-binding agent comprising a branched linker moiety with a reactive group for forming a CBA-drug conjugates; and conjugates so formed. Such conjugates and/or cytotoxic compounds may be effective for treating a range of diseases, such as cancer, with a relatively high activity at a relatively low, non-toxic dose.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361829893P | 2013-05-31 | 2013-05-31 | |
US61/829,893 | 2013-05-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014194030A2 WO2014194030A2 (en) | 2014-12-04 |
WO2014194030A3 true WO2014194030A3 (en) | 2015-01-22 |
Family
ID=50983218
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/039919 WO2014194030A2 (en) | 2013-05-31 | 2014-05-29 | Conjugates comprising cell-binding agents and cytotoxic agents |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014194030A2 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY183572A (en) | 2013-03-15 | 2021-02-26 | Regeneron Pharma | Biologically active molecules, conjugates thereof, and therapeutic uses |
JP6608823B2 (en) | 2013-08-26 | 2019-11-20 | レゲネロン ファーマシューティカルス,インコーポレーテッド | Pharmaceutical compositions containing macrolide diastereomers, methods for their synthesis, and therapeutic uses |
KR101628872B1 (en) | 2014-05-28 | 2016-06-09 | 주식회사 레고켐 바이오사이언스 | Compounds comprising self-immolative group |
CN106267225B (en) * | 2015-05-29 | 2020-03-06 | 上海新理念生物医药科技有限公司 | Trimaleimide-type linker and use thereof |
JP6802840B2 (en) | 2015-06-09 | 2020-12-23 | エックスディーシーエクスプローラー (シャンハイ) カンパニー リミテッド | Antibody-drug conjugates, intermediates, methods for their production, pharmaceutical compositions and applications |
US11413353B2 (en) | 2015-11-25 | 2022-08-16 | Legochem Biosciences, Inc. | Conjugates comprising self-immolative groups and methods related thereto |
AU2016359234B2 (en) * | 2015-11-25 | 2022-09-08 | Legochem Biosciences, Inc. | Conjugates comprising peptide groups and methods related thereto |
CN113599533A (en) | 2015-11-25 | 2021-11-05 | 乐高化学生物科学股份有限公司 | Antibody-drug conjugates comprising branched linkers and methods related thereto |
CN114478801A (en) | 2016-01-25 | 2022-05-13 | 里珍纳龙药品有限公司 | Maytansinoid derivatives, conjugates thereof, and methods of use |
US11654197B2 (en) | 2017-03-29 | 2023-05-23 | Legochem Biosciences, Inc. | Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same |
BR112020022299A2 (en) | 2018-05-09 | 2021-02-23 | Legochem Biosciences, Inc. | compositions and methods related to anti-cd19 antibody-drug conjugates |
KR20210028544A (en) | 2019-09-04 | 2021-03-12 | 주식회사 레고켐 바이오사이언스 | Antibody-drug conjugate comprising antibody binding to antibody against human ROR1 and its use |
KR102465431B1 (en) * | 2020-10-21 | 2022-11-09 | 순천향대학교 산학협력단 | Cell Penetrating Peptide-linker-anti-cancer drug and Pharmaceutical composition for prevention or treatment of colorectal cancer containing the same |
WO2022262516A1 (en) * | 2021-06-18 | 2022-12-22 | 北京海步医药科技有限公司 | Linker and conjugate therefor |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997023243A1 (en) * | 1995-12-22 | 1997-07-03 | Bristol-Myers Squibb Company | Branched hydrazone linkers |
WO1998019705A1 (en) * | 1996-11-05 | 1998-05-14 | Bristol-Myers Squibb Company | Branched peptide linkers |
US20020015691A1 (en) * | 2000-03-31 | 2002-02-07 | Greenwald Richard B. | Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same |
WO2013103707A1 (en) * | 2012-01-03 | 2013-07-11 | Invictus Oncology Pvt. Ltd. | Ligand-targeted molecules and methods thereof |
WO2014064424A1 (en) * | 2012-10-24 | 2014-05-01 | Polytherics Limited | Drug-protein conjugates |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
ATE463573T1 (en) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | PRODUCTION OF AUTOANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US20080152586A1 (en) | 1992-09-25 | 2008-06-26 | Avipep Pty Limited | High avidity polyvalent and polyspecific reagents |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
JPH08175990A (en) | 1994-12-19 | 1996-07-09 | Mitsubishi Chem Corp | Pi3 kinase-inhibiting agent and its production |
JPH08176070A (en) | 1994-12-19 | 1996-07-09 | Mitsubishi Chem Corp | Didepside derivative and pi3 kinase inhibitor |
US6355780B1 (en) | 1995-02-22 | 2002-03-12 | Yeda Research And Development Co. Ltd. | Antibodies to the death domain motifs of regulatory proteins |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
CA2218503C (en) | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
GB9521987D0 (en) | 1995-10-26 | 1996-01-03 | Ludwig Inst Cancer Res | Phosphoinositide 3-kinase modulators |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
ATE225343T1 (en) | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | MATRIX METALLOPROTEASE INHIBITORS |
AU719434B2 (en) | 1996-02-13 | 2000-05-11 | Astrazeneca Ab | Quinazoline derivatives as VEGF inhibitors |
CA2244897C (en) | 1996-03-05 | 2006-04-11 | Zeneca Limited | 4-anilinoquinazoline derivatives |
EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
JP3299975B2 (en) | 1996-07-18 | 2002-07-08 | ファイザー・インク | Phosphinate-based inhibitors of matrix metalloproteases |
US6153609A (en) | 1996-08-23 | 2000-11-28 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
ATE272640T1 (en) | 1997-01-06 | 2004-08-15 | Pfizer | CYCLIC SULFONE DERIVATIVES |
IL131042A (en) | 1997-02-03 | 2004-07-25 | Pfizer Prod Inc | Arylsulfonylamino hydroxamic acid derivatives and pharmaceutical compositions comprising them |
AU5493598A (en) | 1997-02-07 | 1998-08-26 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
TR199901926T2 (en) | 1997-02-11 | 1999-12-21 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
WO1998035985A1 (en) | 1997-02-12 | 1998-08-20 | The Regents Of The University Of Michigan | Protein markers for lung cancer and use thereof |
WO1999006587A2 (en) | 1997-08-01 | 1999-02-11 | Morphosys Ag | Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex |
NZ502309A (en) | 1997-08-08 | 2002-02-01 | Pfizer Prod Inc | Aryloxyarylsulfonylamino hydroxamic acid derivatives and pharmaceutical use |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
JP4462654B2 (en) | 1998-03-26 | 2010-05-12 | ソニー株式会社 | Video material selection device and video material selection method |
PA8469501A1 (en) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | HYDROXAMIDES OF THE ACID (4-ARILSULFONILAMINO) -TETRAHIDROPIRAN-4-CARBOXILICO |
PA8469401A1 (en) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | BICYCLE DERIVATIVES OF HYDROXAMIC ACID |
DK1004578T3 (en) | 1998-11-05 | 2004-06-28 | Pfizer Prod Inc | 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives |
US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
DK1154774T3 (en) | 1999-02-10 | 2005-09-26 | Astrazeneca Ab | Quinazoline derivatives as angiogenesis inhibitors |
SI1676845T1 (en) | 1999-11-05 | 2008-10-31 | Astrazeneca Ab | New quinazoline derivatives |
PT1255752E (en) | 2000-02-15 | 2007-10-17 | Pharmacia & Upjohn Co Llc | Pyrrole substituted 2-indolinone protein kinase inhibitors |
JP2001247477A (en) | 2000-03-03 | 2001-09-11 | Teikoku Hormone Mfg Co Ltd | Antitumor medicine |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
US6403588B1 (en) | 2000-04-27 | 2002-06-11 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazopyridine derivatives |
US7417130B2 (en) | 2000-09-08 | 2008-08-26 | University Of Zurich | Collection of repeat proteins comprising repeat modules |
DE60203260T2 (en) | 2001-01-16 | 2006-02-02 | Glaxo Group Ltd., Greenford | PHARMACEUTICAL COMBINATION CONTAINING A 4-CHINA-ZININAMINE AND PACLITAXEL, CARBOPLATIN OR VINORELBINE FOR THE TREATMENT OF CANCER |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
EP1417976A4 (en) | 2001-07-26 | 2004-09-15 | Santen Pharmaceutical Co Ltd | Remedy for glaucoma comprising as the active ingredient compound having pi3 kinase inhibitory effect |
US6703414B2 (en) | 2001-09-14 | 2004-03-09 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Device and method for treating restenosis |
US6894055B2 (en) | 2001-10-24 | 2005-05-17 | Iconix Pharmaceuticals Inc. | Thieno-2′,3′ -5,6pyrimido[3,4-A]-1,2,4-triazole derivatives as modulators of phoshoinositide 3-kinase |
WO2003035618A2 (en) | 2001-10-24 | 2003-05-01 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase |
CA2464924A1 (en) | 2001-10-30 | 2003-05-08 | Pharmacia Corporation | Heteroaromatic carboxamide derivatives for the treatment of inflammation |
CA2489779A1 (en) | 2002-07-10 | 2004-01-22 | Applied Research Systems Ars Holding N.V. | Use of compounds for increasing spermatozoa motility |
BR0312650A (en) | 2002-07-10 | 2005-05-03 | Applied Research Systems | Azolidinone-vinyl fused benzene derivatives |
US20040092561A1 (en) | 2002-11-07 | 2004-05-13 | Thomas Ruckle | Azolidinone-vinyl fused -benzene derivatives |
ES2544527T3 (en) | 2002-07-31 | 2015-09-01 | Seattle Genetics, Inc. | Drug conjugates and their use to treat cancer, an autoimmune disease or an infectious disease |
WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
CA2504818C (en) | 2002-11-07 | 2013-04-23 | Immunogen, Inc. | Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
CA2564251C (en) | 2004-05-21 | 2018-04-10 | The Uab Research Foundation | Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof |
MXPA06014065A (en) | 2004-06-01 | 2007-01-31 | Genentech Inc | Antibody drug conjugates and methods. |
CN101065151B (en) | 2004-09-23 | 2014-12-10 | 健泰科生物技术公司 | Cysteine engineered antibodies and conjugates |
GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
US8431558B2 (en) | 2004-11-01 | 2013-04-30 | The Regents Of The University Of California | Compositions and methods for modification of biomolecules |
JP2008521828A (en) | 2004-11-29 | 2008-06-26 | シアトル ジェネティックス, インコーポレイテッド | Engineered antibodies and immunoconjugates |
AU2006213662B2 (en) | 2005-02-11 | 2010-08-05 | Immunogen, Inc. | Process for preparing stable drug conjugates |
CA2614512C (en) | 2005-07-08 | 2014-01-07 | University Of Zuerich | Phage display using cotranslational translocation of fusion polypeptides |
WO2007021674A2 (en) | 2005-08-09 | 2007-02-22 | Millennium Pharmaceuticals, Inc. | Method of acylating maytansinol with chiral amino acids |
NZ609752A (en) | 2005-08-24 | 2014-08-29 | Immunogen Inc | Process for preparing maytansinoid antibody conjugates |
GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
WO2007062466A1 (en) | 2005-11-29 | 2007-06-07 | The University Of Sydney | Demibodies: dimerisation-activated therapeutic agents |
EP1996612A4 (en) | 2006-03-03 | 2010-10-20 | Univ Kingston | Compositions for treatment of cancer |
WO2007147213A1 (en) | 2006-06-22 | 2007-12-27 | Walter And Eliza Hall Institute Of Medical Research | Structure of the insulin receptor ectodomain |
US9365629B2 (en) | 2007-09-24 | 2016-06-14 | University Of Zurich | Designed armadillo repeat proteins |
JP5769616B2 (en) | 2008-04-30 | 2015-08-26 | イミュノジェン・インコーポレーテッド | Crosslinkers and their use |
WO2010040147A2 (en) | 2008-10-03 | 2010-04-08 | Advanced Proteome Therapeutics, Inc. | Site-specific n-terminal modifications of proteins and conjugate formation |
AU2009308935B2 (en) | 2008-10-31 | 2015-02-26 | Janssen Biotech, Inc. | Fibronectin type III domain based scaffold compositions, methods and uses |
EP2396011B1 (en) | 2009-02-12 | 2016-04-13 | Janssen Biotech, Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
LT2437790T (en) | 2009-06-03 | 2019-06-10 | Immunogen, Inc. | Conjugation methods |
WO2011075786A1 (en) | 2009-12-23 | 2011-06-30 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them 2 |
KR20230044026A (en) | 2010-02-24 | 2023-03-31 | 이뮤노젠 아이엔씨 | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
DK2563753T6 (en) | 2010-04-27 | 2016-04-04 | Synaffix Bv | Fused cyclooctynforbindelser and their use in metal-free click-reactions |
EP3569256B1 (en) | 2010-04-30 | 2022-06-15 | Janssen Biotech, Inc. | Stabilized fibronectin domain compositions, methods and uses |
KR20220009505A (en) | 2011-03-29 | 2022-01-24 | 이뮤노젠 아이엔씨 | Preparation of maytansinoid antibody conjugates by a one-step process |
-
2014
- 2014-05-29 WO PCT/US2014/039919 patent/WO2014194030A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997023243A1 (en) * | 1995-12-22 | 1997-07-03 | Bristol-Myers Squibb Company | Branched hydrazone linkers |
WO1998019705A1 (en) * | 1996-11-05 | 1998-05-14 | Bristol-Myers Squibb Company | Branched peptide linkers |
US20020015691A1 (en) * | 2000-03-31 | 2002-02-07 | Greenwald Richard B. | Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same |
WO2013103707A1 (en) * | 2012-01-03 | 2013-07-11 | Invictus Oncology Pvt. Ltd. | Ligand-targeted molecules and methods thereof |
WO2014064424A1 (en) * | 2012-10-24 | 2014-05-01 | Polytherics Limited | Drug-protein conjugates |
Non-Patent Citations (4)
Title |
---|
KING H D ET AL: "MONOCLONAL ANTIBODY CONJUGATES OF DOXORUBICIN PREPARED WITH BRANCHED LINKERS: A NOVEL METHOD FOR INCREASING THE POTENCY OF DOXORUBICIN IMMUNOCONJUGATES", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, vol. 10, no. 2, 1 March 1999 (1999-03-01), pages 279 - 288, XP000804254, ISSN: 1043-1802, DOI: 10.1021/BC980100I * |
KING H D ET AL: "MONOCLONAL ANTIBODY CONJUGATES OF DOXORUBICIN PREPARED WITH BRANCHED PEPTIDE LINKERS: INHIBITION OF AGGREGATION BY METHOXYTRIETHYLENEGLYCOL CHAINS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 45, no. 19, 1 January 2002 (2002-01-01), pages 4336 - 4343, XP001193748, ISSN: 0022-2623, DOI: 10.1021/JM020149G * |
ROBERT Y. ZHAO ET AL: "Synthesis and Evaluation of Hydrophilic Linkers for Antibody-Maytansinoid Conjugates", JOURNAL OF MEDICINAL CHEMISTRY, vol. 54, no. 10, 26 May 2011 (2011-05-26), pages 3606 - 3623, XP055046274, ISSN: 0022-2623, DOI: 10.1021/jm2002958 * |
XIUXIA SUN ET AL: "Design of Antibody-Maytansinoid Conjugates Allows for Efficient Detoxification via Liver Metabolism", BIOCONJUGATE CHEMISTRY, vol. 22, no. 4, 20 April 2011 (2011-04-20), pages 728 - 735, XP055096244, ISSN: 1043-1802, DOI: 10.1021/bc100498q * |
Also Published As
Publication number | Publication date |
---|---|
WO2014194030A2 (en) | 2014-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014194030A3 (en) | Conjugates comprising cell-binding agents and cytotoxic agents | |
WO2014134483A3 (en) | Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents | |
WO2014134457A3 (en) | Conjugates comprising cell-binding agents and cytotoxic agents | |
PH12019502018A1 (en) | Compositions, formulations and methods for treating ocular diseases | |
NZ710729A (en) | Amatoxin derivatives | |
IN2015DN00694A (en) | ||
MX2016008444A (en) | Sulfonamide-containing linkage systems for drug conjugates. | |
MY174813A (en) | Cytotoxic and anti-mitotic compounds, and methods of using the same | |
WO2015151079A3 (en) | Auristatin analogues and their conjugates with cell-binding molecules | |
WO2012142237A8 (en) | Fused imidazole derivatives useful as ido inhibitors | |
MX361218B (en) | Spliceostatin analogs. | |
WO2015017821A3 (en) | Therapeutically active compounds and their methods of use | |
NZ710746A (en) | Pyrrolobenzodiazepines and conjugates thereof | |
MX2017013167A (en) | Site-specific antibody-drug conjugates. | |
WO2013072813A3 (en) | Cytotoxic peptides and antibody drug conjugates thereof | |
WO2011098611A3 (en) | Targeted alpha- particle emitting complexes comprising thorium radionuclide hydroxypyridinone containing ligand | |
WO2016127081A8 (en) | Antibody drug conjugates | |
WO2014134486A3 (en) | Conjugates comprising cell-binding agents and cytotoxic agents | |
NZ630465A (en) | Combination therapy involving a vascular disrupting agent and an agent which targets hypoxia | |
WO2013103301A3 (en) | Method for preparing cell targeting conjugates, and the complexes obtained | |
WO2015114166A3 (en) | Targeted drug conjugates | |
WO2014107730A3 (en) | Use of fatty acid niacin conjugates for treating diseases | |
MX2017003476A (en) | Cytotoxic and anti-mitotic compounds, and methods of using the same. | |
TW201613641A (en) | Anti-CD22 antibody-drug conjugates and methods of using thereof | |
WO2012168885A9 (en) | Bisacodyl and its analogues as drugs for use in the treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14732781 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14732781 Country of ref document: EP Kind code of ref document: A2 |